272 related articles for article (PubMed ID: 19000107)
1. Phosphate binders in chronic kidney disease and end-stage renal disease: a patient-centered approach.
Novak JE; Szczech LA
Semin Dial; 2009; 22(1):56-63. PubMed ID: 19000107
[TBL] [Abstract][Full Text] [Related]
2. Calcium-based phosphate binders are appropriate in chronic renal failure.
Friedman EA
Clin J Am Soc Nephrol; 2006 Jul; 1(4):704-9. PubMed ID: 17699276
[TBL] [Abstract][Full Text] [Related]
3. Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial.
Garg JP; Chasan-Taber S; Blair A; Plone M; Bommer J; Raggi P; Chertow GM
Arthritis Rheum; 2005 Jan; 52(1):290-5. PubMed ID: 15641045
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
[TBL] [Abstract][Full Text] [Related]
5. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
6. The case against calcium-based phosphate binders.
Moe SM; Chertow GM
Clin J Am Soc Nephrol; 2006 Jul; 1(4):697-703. PubMed ID: 17699275
[TBL] [Abstract][Full Text] [Related]
7. Control of hyperphosphatemia among patients with ESRD.
Coladonato JA
J Am Soc Nephrol; 2005 Nov; 16 Suppl 2():S107-14. PubMed ID: 16251245
[TBL] [Abstract][Full Text] [Related]
8. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
Molony DA; Stephens BW
Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
[TBL] [Abstract][Full Text] [Related]
9. Phosphate metabolism in the setting of chronic kidney disease: significance and recommendations for treatment.
Kestenbaum B
Semin Dial; 2007; 20(4):286-94. PubMed ID: 17635817
[TBL] [Abstract][Full Text] [Related]
10. Vascular calcification in patients with end-stage renal disease.
Floege J; Ketteler M
Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V59-66. PubMed ID: 15284362
[TBL] [Abstract][Full Text] [Related]
11. Management of hyperphosphataemia in dialysis patients: role of phosphate binders in the elderly.
Lorenzo Sellares V; Torres Ramírez A
Drugs Aging; 2004; 21(3):153-65. PubMed ID: 14979734
[TBL] [Abstract][Full Text] [Related]
12. Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study.
Spiegel DM; Farmer B; Smits G; Chonchol M
J Ren Nutr; 2007 Nov; 17(6):416-22. PubMed ID: 17971314
[TBL] [Abstract][Full Text] [Related]
13. Salivary phosphorus and phosphate content of beverages: implications for the treatment of uremic hyperphosphatemia.
Savica V; Calò LA; Monardo P; Santoro D; Mallamace A; Muraca U; Bellinghieri G
J Ren Nutr; 2009 Jan; 19(1):69-72. PubMed ID: 19121775
[TBL] [Abstract][Full Text] [Related]
14. New developments in the management of hyperphosphatemia in chronic kidney disease.
McIntyre CW
Semin Dial; 2007; 20(4):337-41. PubMed ID: 17635825
[TBL] [Abstract][Full Text] [Related]
15. Phosphorus management in end-stage renal disease.
Finn WF
Semin Dial; 2005; 18(1):8-12. PubMed ID: 15663754
[TBL] [Abstract][Full Text] [Related]
16. [Why do patients with kidney diseases end up with a heart of stone? Disturbances in calcium-phosphate balance and chronic inflammation important causes].
Martola L; Elinder CG; Stenvinkel P
Lakartidningen; 2003 Dec; 100(50):4180-3. PubMed ID: 14717005
[TBL] [Abstract][Full Text] [Related]
17. The role of magnesium binders in chronic kidney disease.
Spiegel DM
Semin Dial; 2007; 20(4):333-6. PubMed ID: 17635824
[TBL] [Abstract][Full Text] [Related]
18. [Management of hyperphosphatemia in dialysis patients: the role of phosphate binders].
Malberti F
G Ital Nefrol; 2010; 27 Suppl 52():S47-54. PubMed ID: 21132662
[TBL] [Abstract][Full Text] [Related]
19. The safety of phosphate binders.
Almirall J; Valenzuela MP
Expert Opin Drug Saf; 2006 Sep; 5(5):675-86. PubMed ID: 16907657
[TBL] [Abstract][Full Text] [Related]
20. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients: results of a randomized clinical trial.
Suki WN;
J Ren Nutr; 2008 Jan; 18(1):91-8. PubMed ID: 18089452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]